Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29597594 | 1.00 | CYP2C19 (0.70) | CYP2C19CYP2C9SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL30214356 | 0.94 | CYP2C19 (0.82) | CYP2C19CYP2C9SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL277284 | 0.89 | CYP2C19 (0.86) | CYP2C19CYP2C9SMN1; SMN2CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9679507 | 0.87 | CYP2C19 (0.83) | CYP2C19CYP2C9SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18536755 | 0.86 | MAPT (0.64) | CYP2C19CYP2C9SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL6830767 | 0.84 | L3MBTL1 (0.57) | CYP2C19SMN1; SMN2CYP1A2CYP3A4L3MBTL1 | |
| SCHEMBL6979199 | 0.84 | CYP2C19 (0.72) | CYP2C19CYP2C9SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL13296375 | 0.83 | MAPT (0.76) | CYP2C19SMN1; SMN2CYP1A2CYP3A4L3MBTL1 | |
| SCHEMBL8622944 | 0.83 | CYP2C19 (0.57) | CYP2C19CYP2C9SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL14017822 | 0.83 | CYP2C19 (0.57) | CYP2C19CYP2C9SMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107981492-B | Preparation method of amber pendant | 钟杰 | 2020-06-19 | — | — | CN | claimed |
| CN-103012451-A | Industrialized preparation method of 3-ethoxycarbonyl-5-pyridine pinacol borate | WUXI APPTEC CO LTD | 2013-04-03 | — | — | CN | claimed |
| EP-0767792-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | claimed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | claimed |
| EP-4747247-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2026-05-27 | — | — | EP | disclosed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-121554416-A | Preparation process of 5-bromonicotinic acid | 嘉兴佰美济华医药科技有限公司 | 2026-02-24 | — | — | CN | disclosed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-12421193-B2 | GPR52 modulators and methods of use | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-09-09 | — | — | US | disclosed |
| US-5559124-A | QUINUCLIDINE DERIVATIVE | TARGACEPT, INC., A CORPORATION OF DELAWARE | 1996-09-24 | — | — | US | disclosed |
| WO-1996023783-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996015123-A1 | PYRIDINE MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5510355-A | ADMINISTERING 2-(3-PYRIDYL)-QUINUCLILIDINE DERIVATIVE TO THE PATIENT UNDERGOING SURGICAL PROCEDURE REQUIRING ANESTHESIA AS A MUSCLE RELEXANT | TARGACEPT, INC., A CORPORATION OF DELAWARE | 1996-04-23 | — | — | US | disclosed |
| WO-1996007410-A2 | DEPOLARIZING SKELETAL MUSCLE RELAXANTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
| EP-0656897-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-14 | — | — | EP | disclosed |
| WO-1994005660-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-03-17 | — | — | WO | disclosed |
| EP-0127276-A2 | Carbonylation process | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | FAAH, FAAH2, MGLL | CYP2C19 575/4885CYP2C9 425/4885SMN1; SMN2 4636/4885 |
| US-12421193-B2 | GPR52 modulators and methods of use | GPR52, GPR68, GPR35 | CYP2C19 2391/4885CYP2C9 3244/4885SMN1; SMN2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.